NATCO Pharma Visakhapatnam Unit Gets US FDA Form 483

NATCO Pharma’s manufacturing facility in Visakhapatnam, Andhra Pradesh, India, received a Form 483 with four observations from the U.S. Food and Drug Administration (US FDA).

This issuance followed a five-day inspection conducted by the US FDA at the plant from August 17 to August 21, 2026.

Understanding the US FDA Form 483

A Form 483 is issued by the US FDA to a company’s management at the conclusion of an inspection when an investigator observes any conditions that, in their judgment, may constitute violations of the Food Drug and Cosmetic Act and related acts.

NATCO Pharma stated its belief that these observations are procedural in nature and expressed confidence in addressing them within the stipulated timelines.

NATCO Pharma’s Business Operations

NATCO Pharma operates across various segments within the pharmaceutical industry, developing and manufacturing a diverse range of products.

Its portfolio includes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients, and crop protection products.

Q1 FY27 Financial Performance

The announcement of the Form 483 follows a period where NATCO Pharma reported a significant decline in its financial results for the first quarter of fiscal year 2027 (Q1 FY27).

• Consolidated net profit saw a decline of 57.04%, settling at Rs 206.50 crore.
• Revenue also fell by 44.68%, reaching Rs 735.20 crore for Q1 FY27.
• These financial figures represent a comparison against the performance recorded in Q1 FY26.

Despite the financial downturn, the company’s stock experienced a slight increase of 0.54%, closing at Rs 882.50 on the BSE on Friday.

Outlook on Compliance

NATCO Pharma remains steadfast in its commitment to resolving the four observations detailed in the Form 483, reiterating its expectation to complete corrective actions promptly.